JPRN-UMIN000030265已完成未知
A single arm, open-label study evaluating the safety and efficacy of ra148 in patients with atopic dermatitis. - A single arm, open-label study evaluating the safety and efficacy of ra148 in patients with atopic dermatitis.
MIE HIFUKA CLINIC0 个研究点目标入组 12 人开始时间: 2017年12月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 49years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with severe skin disorders on test site (both arms) and deemed inappropriate to participate in this study by the doctor. 2) Patients who have a history of hypersensitivity to heparin analog preparation. 3) Pregnant or lactating patients. Patients with suspicion of pregnancy. 4) Patients deemed inappropriate to participate in this study by the principal doctor or investigators. 5) Patients with hemorrhagic blood disease; e.g. Hemophilia, Thrombocytopenia, Purpura, etc. 6) Patients who are expected to promote serious consequences with minimal bleeding. 7) Patients who have undergone climacteric disorder or postmenopausal "hormone replacement therapy"
研究者
相似试验
进行中（未招募）
不适用
An open label, single arm study to assess the safety and immunogenicity of omalizumab liquid administered subcutaneously in a pre-filled safety syringe (75 mg or 150 mg) over a period of 6 months to male and female adolescents and adults with moderate to severe persistent allergic asthmamoderate to severe persistent allergic asthmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2006-005917-36-DEovartis Pharma Services AG100
进行中（未招募）
不适用
Safety and Tolerability of Cinacalcet in Pediatric Subjects With Chronic Kidney Disease and Secondary HyperparathyroidismSecondary hyperparathyroidism in pediatric subjects with chronic kidney disease receiving hemodialysis or peritoneal dialysisMedDRA version: 16.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2011-004618-40-DEAmgen Inc.20
进行中（未招募）
不适用
Safety and Tolerability of Cinacalcet in Pediatric Subjects With ChronicKidney Disease and Secondary HyperparathyroidismSecondary hyperparathyroidism in pediatric subjects with chronic kidney disease receiving hemodialysis or peritoneal dialysisMedDRA version: 18.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2011-004618-40-Outside-EU/EEAAmgen Inc.30
进行中（未招募）
1 期
Safety and Tolerability of Cinacalcet in Pediatric Subjects With Chronic Kidney Disease and Secondary HyperparathyroidismSecondary hyperparathyroidism in pediatric subjects with chronic kidney disease receiving hemodialysis or peritoneal dialysisMedDRA version: 17.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2011-004618-40-ITAmgen Inc.30
进行中（未招募）
1 期
An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Participants with Tuberous Sclerosis Complex (Age 1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) who Experience Inadequately-controlled SeizuresDravet Syndrome, Tuberous sclerosis complex, Lennox-Gastaut SyndromeMedDRA version: 20.0Level: LLTClassification code: 10073682Term: Dravet syndrome Class: 10010331MedDRA version: 21.0Level: PTClassification code: 10080584Term: Tuberous sclerosis complex Class: 100000004850MedDRA version: 20.1Level: PTClassification code: 10048816Term: Lennox-Gastaut syndrome Class: 100000004852CTIS2023-505851-33-00Gw Research Limited27